Acuren Corporation Reports 1.5% Revenue Increase to $313.9 Million in Q2 2025; Adjusted EBITDA Declines to $54.6 Million

Reuters
2025/08/14
Acuren Corporation Reports 1.5% Revenue Increase to $313.9 Million in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025; Adjusted EBITDA Declines to $54.6 Million

Acuren Corporation has announced its financial results for the second quarter of 2025, reporting a revenue of $313.9 million, marking a 1.5% increase year-over-year with an organic growth of 2.0%. The company experienced a decline in its Adjusted EBITDA, recording $54.6 million compared to $59.1 million in the prior year period. The Adjusted EBITDA margin also decreased to 17.4% from 19.1% in the previous year. These changes reflect a normalized business mix and added public company costs. The company completed its merger with NV5 Global, Inc. on August 4, 2025, positioning Acuren as a leading provider in the TICC and engineering services market with a combined $2 billion entity. However, the financial results of NV5 were not included in Acuren's second quarter results as the merger was finalized post-reporting period. Acuren plans to update its financial outlook to incorporate the combined business with NV5 and expects to release refreshed guidance, including anticipated revenue and Adjusted EBITDA ranges, in its third quarter earnings results in November 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acuren Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814078997) on August 14, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10